-
1.发明授权公开(公告)号：US08038991B1
公开(公告)日：2011-10-18
申请号：US11933922
申请日：2007-11-01
申请人： John J. Stankus , Eugene Michal , Mikael Trollsas , Brandon Katz , Shubhayu Basu
发明人： John J. Stankus , Eugene Michal , Mikael Trollsas , Brandon Katz , Shubhayu Basu
IPC分类号： C12N5/00
CPC分类号： A61K31/00 , A61K9/0024 , A61K31/728 , A61K31/78 , A61K31/79 , A61K35/16 , A61K35/28 , A61K35/34 , A61K35/35 , A61K38/40 , A61K45/06 , A61K47/36 , A61L27/26 , A61L27/3804 , A61L27/3839 , A61L2430/20 , A61K2300/00 , C08L5/08
摘要： Embodiments of single component bioscaffolding systems formed of a hydrogel such as hyaluronic acid or salt thereof are described. The hyaluronic acid or salt thereof may be dissolved in a buffer, plasma, or combination thereof to minimize adverse immunogenic responses when applied to a treatment site. Additionally, the hydrogel component includes stem cells to facilitate angiogenesis or facilitate tissue repair and/or regeneration of ischemic tissue, particularly in compromised cardiac tissue. The bioscaffolding may also be formed on a stent or a cardiac medical device.
摘要翻译： 描述了由诸如透明质酸或其盐的水凝胶形成的单组分生物支架系统的实施方案。 透明质酸或其盐可以溶解在缓冲液，血浆或其组合中，以在施用于治疗部位时使不利的免疫原性反应最小化。 此外，水凝胶组分包括促进血管发生的干细胞，或促进缺血组织的组织修复和/或再生，特别是在受损的心脏组织中。 生物支架也可以形成在支架或心脏医疗装置上。
-
2.发明申请Modified Two-Component Gelation Systems, Methods of Use and Methods of Manufacture 有权改进的双组分凝胶化系统，使用方法和制造方法公开(公告)号：US20100196313A1
公开(公告)日：2010-08-05
申请号：US12756092
申请日：2010-04-07
CPC分类号： A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
摘要： Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
摘要翻译： 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有至少一个细胞粘附位点的物质，其在约6.5的pH下在第一缓冲液中合并。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送至治疗区域，例如心肌梗死后区域。
-
3.发明授权Modified two-component gelation systems, methods of use and methods of manufacture 有权改进的双组分凝胶化系统，使用方法和制造方法公开(公告)号：US08486387B2
公开(公告)日：2013-07-16
申请号：US12756119
申请日：2010-04-07
CPC分类号： A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
摘要： Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
摘要翻译： 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有至少一个细胞粘附位点的物质，其在约6.5的pH下在第一缓冲液中合并。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送至治疗区域，例如心肌梗死后区域。
-
公开(公告)号：US08486386B2
公开(公告)日：2013-07-16
申请号：US12756092
申请日：2010-04-07
CPC分类号： A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
摘要： Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
-
公开(公告)号：US20100196314A1
公开(公告)日：2010-08-05
申请号：US12756119
申请日：2010-04-07
CPC分类号： A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
摘要： Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
-
6.发明授权Modified two-component gelation systems, methods of use and methods of manufacture 失效改进的双组分凝胶化系统，使用方法和制造方法公开(公告)号：US07732190B2
公开(公告)日：2010-06-08
申请号：US11496824
申请日：2006-07-31
CPC分类号： A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
摘要： Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
摘要翻译： 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有至少一个细胞粘附位点的物质，其在约6.5的pH下在第一缓冲液中合并。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送至治疗区域，例如心肌梗死后区域。
-
7.发明申请Modified two-component gelation systems, methods of use and methods of manufacture 失效改进的双组分凝胶化系统，使用方法和制造方法公开(公告)号：US20080025943A1
公开(公告)日：2008-01-31
申请号：US11496824
申请日：2006-07-31
CPC分类号： A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
摘要： Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
摘要翻译： 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有在约6.5的pH下在第一缓冲液中组合的至少一个细胞粘附位点的物质。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送到治疗区域，例如心肌梗死后区域。
-
公开(公告)号：US08888675B2
公开(公告)日：2014-11-18
申请号：US12855469
申请日：2010-08-12
申请人： John J. Stankus , Barbara E. Stamberg , Pamela A. Kramer-Brown , Jesus Magana , Shubhayu Basu , Yuet Mei Khong , Florian N. Ludwig
发明人： John J. Stankus , Barbara E. Stamberg , Pamela A. Kramer-Brown , Jesus Magana , Shubhayu Basu , Yuet Mei Khong , Florian N. Ludwig
IPC分类号： A61F2/00 , A61N1/362 , A61B17/12 , A61B17/064 , A61F2/24 , A61B17/068
CPC分类号： A61F2/2487 , A61B17/064 , A61B17/068 , A61B17/12122 , A61B17/12181 , A61B17/12186 , A61B17/12195 , A61B2017/0647 , A61L2430/20
摘要： Apparatus and methods are disclosed for supporting ischemic tissue of the heart using scaffolds that may be placed within the heart percutaneously. A scaffold assembly may include a layer of biocompatible material detachably secured to a placement rod, such that the placement rod may be used to urge the layer of biocompatible material through a catheter to adjacent an area of ischemic tissue. Anchors may secure the layer of material to the myocardium. Multiple layers of biocompatible material may be placed in the ventricle separately to form the scaffold. In some embodiments, a scaffold is formed or reinforced by injecting a polymer, such as a visco-elastic foam, around an inflatable member inflated within a ventricle.
摘要翻译： 公开了用于支持心脏的缺血组织的装置和方法，所述支架可以经皮放置在心脏内的支架。 支架组件可以包括可拆卸地固定到放置杆的生物相容性材料层，使得放置杆可以用于通过导管将生物相容性材料层推动到邻近缺血组织的区域。 锚固体可以将材料层固定到心肌。 可以将多层生物相容性材料分别放置在心室中以形成支架。 在一些实施方案中，通过将聚合物（例如粘弹性泡沫）注射到在心室内膨胀的可充气构件的周围形成或增强支架。
-
9.发明授权Multiple growth factor compositions, methods of fabrication, and methods of treatment 失效多重生长因子组合物，制备方法和治疗方法公开(公告)号：US08703180B1
公开(公告)日：2014-04-22
申请号：US11877635
申请日：2007-10-23
申请人： John J. Stankus , Florian N. Ludwig , Evgenia Mandrusov , Liangxuan Zhang , Hong Ma , Jinping Wan , Shubhayu Basu
发明人： John J. Stankus , Florian N. Ludwig , Evgenia Mandrusov , Liangxuan Zhang , Hong Ma , Jinping Wan , Shubhayu Basu
CPC分类号： A61K38/30 , A61K9/06 , A61K9/127 , A61K35/34 , A61K38/18 , A61K38/1825 , A61K38/1833 , A61K38/1858 , A61K38/1866 , A61K38/1891 , A61K38/19 , A61K38/193 , A61K38/57 , A61K45/06 , A61L27/3834 , A61L27/52 , A61L27/54 , A61L27/58 , A61L2300/414 , A61L2300/604 , A61L2300/626 , A61L2430/20 , A61K2300/00
摘要： Disclosed are compositions with sustained-release carriers associated with at least two different types of growth factors and methods of fabrication and treatments thereof. In some embodiments, simultaneous release of the growth factors may be preferred while in other embodiments, sequential release of the growth factors may be preferred. Application of at least two growth factors to an injury site, e.g., compromised cardiac tissue caused by, for example, myocardial infarction or ischemic heart failure, may better mimic and induce the complex growth factor signaling pathways necessary to improve cardiac function. When applied to a patient after a myocardial infarction or ischemic heart failure, multiple growth factors within a sustained-release carrier platform or platforms may cause a synergistic effect on injected cells intending to alleviate left ventricle remodeling. Methods of treatment include percutaneous, sub-xiphoid, and open chest methods using catheters and/or syringes.
摘要翻译： 公开了具有与至少两种不同类型的生长因子相关联的持续释放载体的组合物及其制备和处理方法。 在一些实施方案中，生长因子的同时释放可以是优选的，而在其它实施方案中，生长因子的顺序释放可能是优选的。 至少两个生长因子施加到损伤部位，例如由心肌梗塞或缺血性心力衰竭引起的受损的心脏组织可以更好地模拟和诱导改善心脏功能所必需的复合生长因子信号传导途径。 当在心肌梗死或缺血性心力衰竭后应用于患者时，持续释放载体平台或平台内的多个生长因子可能对旨在减轻左心室重塑的注射细胞产生协同效应。 治疗方法包括使用导管和/或注射器的经皮，亚剑虫和胸部开胸方法。
-
公开(公告)号：US20120041257A1
公开(公告)日：2012-02-16
申请号：US12855469
申请日：2010-08-12
申请人： John J. Stankus , Barbara E. Stamberg , Pamela A. Kramer-Brown , Jesus Magana , Shubhayu Basu , Yuet Mei Khong , Florian N. Ludwig
发明人： John J. Stankus , Barbara E. Stamberg , Pamela A. Kramer-Brown , Jesus Magana , Shubhayu Basu , Yuet Mei Khong , Florian N. Ludwig
IPC分类号： A61F2/00
CPC分类号： A61F2/2487 , A61B17/064 , A61B17/068 , A61B17/12122 , A61B17/12181 , A61B17/12186 , A61B17/12195 , A61B2017/0647 , A61L2430/20
摘要： Apparatus and methods are disclosed for supporting ischemic tissue of the heart using scaffolds that may be placed within the heart percutaneously. A scaffold assembly may include a layer of biocompatible material detachably secured to a placement rod, such that the placement rod may be used to urge the layer of biocompatible material through a catheter to adjacent an area of ischemic tissue. Anchors may secure the layer of material to the myocardium. Multiple layers of biocompatible material may be placed in the ventricle separately to form the scaffold. In some embodiments, a scaffold is formed or reinforced by injecting a polymer, such as a visco-elastic foam, around an inflatable member inflated within a ventricle.
摘要翻译： 公开了用于支持心脏的缺血组织的装置和方法，所述支架可以经皮放置在心脏内的支架。 支架组件可以包括可拆卸地固定到放置杆的生物相容性材料层，使得放置杆可以用于通过导管将生物相容性材料层推动到邻近缺血组织的区域。 锚固体可以将材料层固定到心肌。 可以将多层生物相容性材料分别放置在心室中以形成支架。 在一些实施方案中，通过将聚合物（例如粘弹性泡沫）注射到在心室内膨胀的可充气构件的周围形成或增强支架。
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.03 秒)